A PATIENT-REPORTED OUTCOME MEASURE FOR SYMPTOMS AND SYMPTOM BURDEN OF ACUTE MYELOID LEUKEMIA (AML) AND MYELODYSPLASTIC SYNDROME (MDS).

被引：0
|
作者：
Williams, Loretta A. [1 ]
Gonzalez, Araceli Garcia [1 ]
Cortes, Jorge E. [1 ]
Garcia-Manero, Guillermo [1 ]
Mendoza, Tito R. [1 ]
Cleeland, Charles S. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
ONCOLOGY NURSING FORUM | 2016年 / 43卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
E-50
引用
收藏
页码：59 / 60
页数：2
相关论文
共 50 条
  • [21] Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia
    Feldman, EJ
    Seiter, KP
    Ahmed, T
    Baskind, P
    Arlin, ZA
    LEUKEMIA, 1996, 10 (01) : 40 - 42
  • [22] Transformation of myelodysplastic syndrome (MDS) to hypocellular Acute Myeloid Leukemia (AML) post renal transplant.
    Hasni, K
    Gunnala, V
    Shah, M
    Hoang, T
    Kung, SC
    Brodsky, I
    Kumar, MA
    Heifets, M
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 923A - 923A
  • [23] Detection of FLT3 gene mutations in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)
    Andrei, A.
    Crisan, D.
    Meng, X.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2006, 8 (05): : 639 - 639
  • [24] Combinations of topotecan and liposomal daunorubicin (Daunoxome) in refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
    Giles, FJ
    Kantarjian, HM
    Cortes, JE
    Koller, C
    Thomas, D
    O'Brien, SM
    Estey, E
    Beran, M
    BLOOD, 1999, 94 (10) : 230B - 230B
  • [25] Outcome of Patients (pts) Treated for Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (s AML) After Azacitidine (AZA) Failure
    Prebet, Thomas
    Gore, Steven D.
    Esterni, Benjamin
    Itzykson, Raphael
    Thepot, Sylvain
    Beach, C. L.
    Fenaux, Pierre
    Vey, Norbert
    BLOOD, 2010, 116 (21) : 199 - 199
  • [26] Patient-reported cognitive symptoms and a patient-reported outcome measure of cognitive function in depression
    Forsyth, B.
    Fehnel, S.
    Danchenko, N.
    Francois, C.
    Brevig, T.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2012, 22 : S229 - S230
  • [27] WHO classification af acute myeloid leukaemia (AML) and the myelodysplastic syndrome (MDS)
    Haferlach, T
    Schoch, C
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2002, 127 (09) : 447 - 450
  • [28] SUCCESSFUL RE-TREATMENT WITH AZACITIDINE IN A PATIENT WITH MYELODYSPLASTIC SYNDROME (MDS) EVOLUTED INTO ACUTE MYELOID LEUKEMIA (AML) AFTER THE SUSPENSION OF THIS AGENT
    Niscola, P.
    Tendas, A.
    Cupelli, L.
    Scaramucci, L.
    Giovannini, M.
    Fratoni, S.
    de Fabritiis, P.
    LEUKEMIA RESEARCH, 2015, 39 : S137 - S138
  • [29] Advanced care planning (ACP) intervention for older patient with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
    LoCastro, Marissa
    Sanapala, Chandrika
    Watson, Erin
    Kluger, Benzi
    Norton, Sally
    Bernacki, Rachelle
    Carroll, Thomas
    Klepin, Heidi D.
    Mendler, Jason
    Loh, Kah Poh
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E19004 - E19004
  • [30] Development of a list of Symptom Items to Measure Patient-reported Outcome Symptoms of Hepatobiliary and Pancreatic Malignancies
    Zhan Yinxia
    Zhang Jingyu
    Shi Qiuling
    QUALITY OF LIFE RESEARCH, 2022, 31 : S142 - S143
12345